| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00535-016-1270-5 |
| P698 | PubMed publication ID | 27699721 |
| P50 | author | Tetsuya Hosaka | Q56223851 |
| Norio Akuta | Q87747459 | ||
| Shunichiro Fujiyama | Q88224889 | ||
| Yusuke Kawamura | Q90407021 | ||
| Hitomi Sezaki | Q92198438 | ||
| Kenji Ikeda | Q114433562 | ||
| Hiromitsu Kumada | Q114433568 | ||
| Fumitaka Suzuki | Q114923480 | ||
| Masahiro Kobayashi | Q114923755 | ||
| Yoshiyuki Suzuki | Q114923935 | ||
| Yasuji Arase | Q114924322 | ||
| Satoshi Saito | Q114924602 | ||
| Mariko Kobayashi | Q114924823 | ||
| P2093 | author name string | Yukiko Suzuki | |
| Rie Mineta | |||
| P2860 | cites work | Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan. | Q45359396 |
| Classification of hepatitis B virus genotypes by the PCR-Invader method with genotype-specific probes | Q45412953 | ||
| Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants | Q45420743 | ||
| Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. | Q45423363 | ||
| Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients | Q46540171 | ||
| Changes in viral loads of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy | Q56898879 | ||
| Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: An international multicenter cohort study | Q58097173 | ||
| Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients | Q84280056 | ||
| Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B | Q28212394 | ||
| Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product | Q30732505 | ||
| Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir | Q33857643 | ||
| Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan | Q34054719 | ||
| Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study | Q34317204 | ||
| Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load | Q37346823 | ||
| Hepatitis B virus resistance to nucleos(t)ide analogues. | Q37593697 | ||
| In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents | Q40115548 | ||
| Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus | Q40262602 | ||
| Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. | Q40375525 | ||
| Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. | Q40543517 | ||
| Tenofovir-based rescue therapy for chronic hepatitis B patients who had failed treatment with lamivudine, adefovir, and entecavir | Q40940597 | ||
| Entecavir plus tenofovir combination therapy in patients with multidrug-resistant chronic hepatitis B: results of a multicentre, prospective study. | Q40967783 | ||
| Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial. | Q41175515 | ||
| Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus | Q41349327 | ||
| No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. | Q42277100 | ||
| Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine | Q42278002 | ||
| Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. | Q42678962 | ||
| No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus | Q42693130 | ||
| Clinical and virological effects of long-term (over 5 years) lamivudine therapy | Q43158113 | ||
| Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues | Q43226767 | ||
| Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy | Q44225016 | ||
| The amino acid substitutions rtP177G and rtF249A in the reverse transcriptase domain of hepatitis B virus polymerase reduce the susceptibility to tenofovir. | Q44670160 | ||
| In vitro characterization of viral fitness of therapy-resistant hepatitis B variants | Q44688075 | ||
| P433 | issue | 5 | |
| P921 | main subject | chronic hepatitis B | Q55779876 |
| tenofovir | Q155954 | ||
| P304 | page(s) | 641-651 | |
| P577 | publication date | 2016-10-03 | |
| P1433 | published in | Journal of Gastroenterology | Q15764399 |
| P1476 | title | Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs | |
| P478 | volume | 52 |
Search more.